Comparative analysis of anxiety-depressive spectrum disorders in patients with rheumatic diseases

Лисицына, Т. А.; Андреевна, Лисицына Татьяна; Veltishchev, D.; Юрьевич, Вельтищев Дмитрий; Seravina, O.; Феликсовна, Серавина Ольга; Kovalevskaya, O.; Starovoytova, M N; Николаевна, Старовойтова Майя; Desinova, O.; Викторовна, Десинова Оксана; Абрамкин, А. А.; Анатольевич, Абрамкин Антон; Ovcharov, Pavel; Сергеевич, Овчаров Павел; Vasilev, V.; Иванович, Васильев Владимир; Alekberova, Z S; Садуллаевна, Алекберова Земфира; Krasnov, Valery N.; Николаевич, Краснов Валерий; Насонов, Е. Л.; Львович, Насонов Евгений

doi:10.26442/terarkh201890530-37

“…Behçet syndrome were reported to be 52%, 50%, 41%, and 38%, respectively [30]. The prevalence of anxiety in the SpA group was similar to the previous study [31], whereas the prevalence of anxiety in the FMF patient group was higher than the other groups.…”

Section: Discussionsupporting

confidence: 82%

Effect of COVID-19 Pandemic on Anxiety in Rheumatology Patients Taking Immunosuppressive Drugs

Duran

¹

,

Açıkgöz

²

,

Gürbüz

³

et al. 2020

Preprint

View full text Add to dashboard Cite

Introduction: Coronavirus disease 2019 (COVID-19) pandemic is a public health emergency that is causing international concern. Patients with medical comorbidities are more likely to be infected and have a worse prognosis. The purpose of this study was to determine the prevalence of anxiety due to COVID-19 pandemic in patients with rheumatic and musculoskeletal diseases (RMDs) who used immunosuppressive drugs during the initial stage of the COVID-19 pandemic and to identify the risk and protective factors that cause anxiety.Methods: A total of 145 patients with RMDs aged ≥18 years who used regular immunosuppressive drugs and 95 healthy controls were included in the study. An anonymous survey comprising questions regarding the COVID-19 pandemic was used, and the Beck anxiety inventory (BAI) was used to measure the anxiety levels of participants. Additional information was collected such as demographic data, current RMDs, immunosuppressive drugs used, information and concerns about COVID-19, and the source of information about COVID-19.Results: About 42.1% patients reported that the epidemic caused concern due to the drug they were using, and 33.8% rated their concerns as moderate and severe. The BAI scores of patients and healthy controls were 4 (0-52) and 3 (0-18) respectively. According to the BAI scores, 16.5% patients had moderate to severe anxiety symptoms; and comparison of the groups showed that the anxiety level of the patient group was significantly higher (38.6% vs. 18.9%, p=0.001). Female had more anxiety symptoms in both groups (p<0.005). In addition, anxiety was lower in patients with higher education levels (p=0.039).Conclusion: It should be ensured that patients in the high-risk group are not provided false information, the patients are individually informed, and they trust the treatment team. Providing online or smartphone-based psychoeducation and psychological interventions may be considered for these patients with high anxiety levels.

show abstract

“…A study that evaluated anxiety disorder in patients with rheumatic disease, anxiety was reported in 44.4% patients. The prevalence of anxiety in patients with RA, primary Sjögren syndrome, systemic lupus erythematosus, and Behçet syndrome were reported to be 52%, 50%, 41%, and 38%, respectively (30). The prevalence of anxiety in the SpA group was similar to the previous study (31), whereas the prevalence of anxiety in the FMF patient group was higher than the other groups.…”

Section: Discussionsupporting

confidence: 79%

Effect of COVID-19 Pandemic on Anxiety in Rheumatology Patients Taking Immunosuppressive Drugs

Duran

¹

,

Açıkgöz

²

,

Gürbüz

³

et al. 2020

Preprint

0

View full text Add to dashboard Cite

Introduction: Coronavirus disease 2019 (COVID-19) pandemic is a public health emergency that is causing international concern. Patients with medical comorbidities are more likely to be infected and have a worse prognosis. The purpose of this study was to determine the prevalence of anxiety due to COVID-19 pandemic in patients with rheumatic and musculoskeletal diseases (RMDs) who used immunosuppressive drugs during the initial stage of the COVID-19 pandemic and to identify the risk and protective factors that cause anxiety.Methods: A total of 145 patients with RMDs aged ≥18 years who used regular immunosuppressive drugs and 95 healthy controls were included in the study. An anonymous survey comprising questions regarding the COVID-19 pandemic was used, and the Beck anxiety inventory (BAI) was used to measure the anxiety levels of participants. Additional information was collected such as demographic data, current RMDs, immunosuppressive drugs used, information and concerns about COVID-19, and the source of information about COVID-19.Results: About 42.1% patients reported that the epidemic caused concern due to the drug they were using, and 33.8% rated their concerns as moderate and severe. The BAI scores of patients and healthy controls were 4 (0-52) and 3 (0-18) respectively. According to the BAI scores, 16.5% patients had moderate to severe anxiety symptoms; and comparison of the groups showed that the anxiety level of the patient group was significantly higher (38.6% vs. 18.9%, p=0.001). Female had more anxiety symptoms in both groups (p<0.005). In addition, anxiety was lower in patients with higher education levels (p=0.039).Conclusion: It should be ensured that patients in the high-risk group are not provided false information, the patients are individually informed, and they trust the treatment team. Providing online or smartphone-based psychoeducation and psychological interventions may be considered for these patients with high anxiety levels.

show abstract

“…In accordance with the ICD-10/DSM-IV, depressive disorders were identified in 63% of patients overall, including 73% of patients with RA, 50% of patients with SLE, and 49% of pSS. Anxiety disorders were reported in 61.5% of patients overall, including 25% of patients with pSS, 24.5% of patients with SLE and 23% of patients with RA [22]. This highlights the high prevalence of psychological disorders in autoimmune diseases.…”

Section: Association Between Autoimmune Dry Eye and Mental Healthmentioning

confidence: 86%

“…An additional approach is required in patients with unsatisfactory response to the adequate conventional dry eye treatments and near normal ocular surface condition, given the higher prevalence of psychological disorders in autoimmune diseases [20][21][22][23] and positive correlation between mental health status and severity of dry eye symptoms [26,58,61].…”

Section: Management Of Refractory Ocular Pain In Spite Of Adequate Dry Eye Treatmentmentioning

confidence: 99%

Autoimmune Dry Eye without Significant Ocular Surface Co-Morbidities and Mental Health

Ashena

¹

,

Dashputra

²

,

Nanavaty

³

2020

Vision

View full text Add to dashboard Cite

Dry eye symptoms can negatively affect the psychological, physical, and social functioning, which can potentially impair the health-related quality of life. This review evaluated the association between autoimmune related dry eye in the absence of significant ocular surface co-morbidities and mental health. This review found a significantly higher prevalence of mental health disorders (such as depression and anxiety) in systemic lupus erythematous, rheumatoid arthritis, systemic sclerosis, Behcet’s disease, and primary Sjogren’s syndrome patients when compared to the general population. Moreover, patients with depression and anxiety interpret ocular sensations differently than healthy controls and the perception of dry eye symptoms can be influenced by their mood. Somatization is common in depression, and this could influence the perception of ocular discomfort. Anti-depressants and anxiolytics with their potential side effects on the tear film status may also contribute or aggravate the dry eye symptoms in these patients. Although ophthalmologists manage the dry eye disease, as per standardized algorithms, they should be mindful of different ocular sensation interpretation and coexistent mental health issues in a large number of this patient group and initiate a multidisciplinary management plan in certain cases. While rheumatologists look after their autoimmune condition, it may be worth liaising with GP and/or psychiatrist colleagues in order to address their neuropathic type pain and mental health co-morbidities.

show abstract

Comparative analysis of anxiety-depressive spectrum disorders in patients with rheumatic diseases

Cited by 17 publications

References 0 publications

Effect of COVID-19 Pandemic on Anxiety in Rheumatology Patients Taking Immunosuppressive Drugs

Effect of COVID-19 Pandemic on Anxiety in Rheumatology Patients Taking Immunosuppressive Drugs

Effect of COVID-19 Pandemic on Anxiety in Rheumatology Patients Taking Immunosuppressive Drugs

Autoimmune Dry Eye without Significant Ocular Surface Co-Morbidities and Mental Health

Contact Info

Product

Resources

About